These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17686865)

  • 1. Infectivity and neutralization of simian immunodeficiency virus with FLAG epitope insertion in gp120 variable loops.
    Laird ME; Desrosiers RC
    J Virol; 2007 Oct; 81(20):10838-48. PubMed ID: 17686865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus.
    Yuste E; Johnson W; Pavlakis GN; Desrosiers RC
    J Virol; 2005 Oct; 79(19):12455-63. PubMed ID: 16160173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
    Yuste E; Sanford HB; Carmody J; Bixby J; Little S; Zwick MB; Greenough T; Burton DR; Richman DD; Desrosiers RC; Johnson WE
    J Virol; 2006 Mar; 80(6):3030-41. PubMed ID: 16501112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities.
    Johnson WE; Sanford H; Schwall L; Burton DR; Parren PW; Robinson JE; Desrosiers RC
    J Virol; 2003 Sep; 77(18):9993-10003. PubMed ID: 12941910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope.
    Johnson WE; Morgan J; Reitter J; Puffer BA; Czajak S; Doms RW; Desrosiers RC
    J Virol; 2002 Mar; 76(5):2075-86. PubMed ID: 11836385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.
    Means RE; Matthews T; Hoxie JA; Malim MH; Kodama T; Desrosiers RC
    J Virol; 2001 Apr; 75(8):3903-15. PubMed ID: 11264379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of two N-linked glycosylation sites within the core of the simian immunodeficiency virus glycoprotein whose removal enhances sensitivity to soluble CD4.
    Pikora C; Wittish C; Desrosiers RC
    J Virol; 2005 Oct; 79(19):12575-83. PubMed ID: 16160185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain.
    Cole KS; Alvarez M; Elliott DH; Lam H; Martin E; Chau T; Micken K; Rowles JL; Clements JE; Murphey-Corb M; Montelaro RC; Robinson JE
    Virology; 2001 Nov; 290(1):59-73. PubMed ID: 11883006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response.
    Laird ME; Igarashi T; Martin MA; Desrosiers RC
    J Virol; 2008 Nov; 82(22):11054-65. PubMed ID: 18768967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies.
    Kent KA; Rud E; Corcoran T; Powell C; Thiriart C; Collignon C; Stott EJ
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1147-51. PubMed ID: 1380261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein.
    Liang X; Munshi S; Shendure J; Mark G; Davies ME; Freed DC; Montefiori DC; Shiver JW
    Vaccine; 1999 Jul; 17(22):2862-72. PubMed ID: 10438057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of natural sequence variation on recognition by monoclonal antibodies neutralize simian immunodeficiency virus infectivity.
    Choi WS; Collignon C; Thiriart C; Burns DP; Stott EJ; Kent KA; Desrosiers RC
    J Virol; 1994 Sep; 68(9):5395-402. PubMed ID: 7520089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
    Losman B; Bolmstedt A; Schønning K; Björndal A ; Westin C; Fenyö EM; Olofsson S
    AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1067-76. PubMed ID: 11485624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys.
    Etemad-Moghadam B; Karlsson GB; Halloran M; Sun Y; Schenten D; Fernandes M; Letvin NL; Sodroski J
    J Virol; 1998 Oct; 72(10):8437-45. PubMed ID: 9733899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys.
    Si Z; Cayabyab M; Sodroski J
    J Virol; 2001 May; 75(9):4208-18. PubMed ID: 11287570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques.
    Silvera P; Flanagan B; Kent K; Rud E; Powell C; Corcoran T; Bruck C; Thiriart C; Haigwood NL; Stott EJ
    AIDS Res Hum Retroviruses; 1994 Oct; 10(10):1295-304. PubMed ID: 7848685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigenic variation of SIV: mutations in V4 alter the neutralization profile.
    Kinsey NE; Anderson MG; Unangst TJ; Joag SV; Narayan O; Zink MC; Clements JE
    Virology; 1996 Jul; 221(1):14-21. PubMed ID: 8661410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
    Martín J; LaBranche CC; González-Scarano F
    J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.